ema semaglutide naion june 2025 A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no Meeting highlights from the Pharmacovigilance

Early studies and real-world usage suggest that Tirzepatide may yield greater weight reduction in certain patients, especially when compounded and administered under medical supervision

Retatrutide is a triple-receptor agonist that activates GLP-1, GIP, and glucagon receptors, but it is still in clinical development

(5) GPX1 rs1800668*A

Until these trials report and a regulator reviews them, every retatrutide result remains investigational, with no approval date

[DOI] [PubMed] [Google Scholar] 42.Soto C, Prez J, Garca V, Ura E, Vadillo M, Raya L

Visible particles or debris Hold your vial or pen up to a light source and look carefully